Πλοήγηση ανά Θέμα "programmed death 1 receptor"
Αποτελέσματα 1-10 από 10
-
Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures
(2021)The development of follicular helper CD4 T (TFH) cells is a dynamic process resulting in a heterogenous pool of TFH subsets. However, the cellular and molecular determinants of this heterogeneity and the possible mechanistic ... -
An Activating Janus kinase-3 mutation is associated with cytotoxic T lymphocyte antigen-4-dependent Immune dysregulation syndrome
(2017)Heterozygous mutations in the cytotoxic T lymphocyte antigen-4 (CTLA-4) are associated with lymphadenopathy, autoimmunity, immune dysregulation, and hypogammaglobulinemia in about 70% of the carriers. So far, the incomplete ... -
Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient
(2021)Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the ... -
CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
(2019)Background: Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed death ligand (PD-L)1 axis, this study was designed in order to evaluate whether there is a correlation ... -
High-risk pituitary adenomas and strategies for predicting response to treatment
(2022)High-risk pituitary adenomas are aggressive. They show clinical and imaging features similar to those of carcinomas, including infiltration of the surrounding brain structures, but lack cerebrospinal or systemic metastases. ... -
Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
(2022)Introduction: The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or ... -
On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells
(2019)Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and ... -
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer
(2019)The integration of immunotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC) has revolutionized the approach of the prevalent type of lung cancer. Although PD-1 and its ligands (PD-L1 and PD-L2) are ... -
-
Small extracellular vesicles in pre-therapy plasma predict clinical outcome in non-small-cell lung cancer patients
(2021)The potential use of plasma-derived small extracellular vesicles (sEV) as predictors of response to therapy and clinical outcome in chemotherapy-naïve patients with non-small-cell lung cancer (NSCLC) was explored. sEV were ...